Last edition
News about Market
Pfizer Raises 2025 Profit Forecast After Strong Q2; Adjusted EPS Seen at USD 2.90-3.10
Pfizer has raised its full-year adjusted earnings per share (EPS) guidance to a range of USD 2.90–3.10, up from its prior outlook of USD 2.80–3.00, following strong second-quarter results that beat market expectations.
Market | 06/08/2025 | By Darshana | 240
US Tariffs Pose Serious Challenges for India's Key Export Sectors, Including Pharma: GlobalData
GlobalData has warned that the US tariffs, coupled with penalties linked to India’s dealings with Russian energy and military supplies, could pose serious challenges for key export sectors, including electronics, pharmaceuticals, automobiles, and textiles.
Market | 05/08/2025 | By Dineshwori | 505
India's Pharma Sector Attracts Over INR 2,450 Crore in July, Driven by Late-Stage Mega Deals
India’s pharmaceutical sector raised USD 294 million (approximately INR 2,450 crore) across 18 deals in July 2025, according to data from Tracxn.
Market | 04/08/2025 | By Darshana | 453
Despite the dip in profit, the company recorded a 9.5% rise in total revenue from operations, reaching INR 13,851.4 crore, up from INR 12,652.75 crore a year earlier. This growth was supported by solid performance across geographies, according to the company.
Market | 01/08/2025 | By Darshana | 304
GSK Q2 Sales Hit GBP 8 Billion, Driven Mainly by Specialty Medicines
GSK has delivered robust second-quarter 2025 results, fueled primarily by strong growth in its Specialty Medicines portfolio.
Market | 31/07/2025 | By Dineshwori | 388
Indegene Named Leader in Life Sciences AI and Analytics by Everest Group
Global research and consulting firm Everest Group has named Indegene a Leader in its Life Sciences AI and Analytics Services” for Commercial PEAK Matrix Assessment 2025.
Market | 31/07/2025 | By Dineshwori | 232
Strides Pharma Q1 FY26 PAT Soars 81% YoY; EBITDA Margin Expands to 19.5%
Strides Pharma Science Ltd has reported a robust financial performance for the first quarter of FY26, with consolidated revenue reaching INR 1,119.7 crore — a 6.2 percent increase from INR 1,053.9 crore recorded in the same quarter of the previous fiscal year.
Market | 30/07/2025 | By Darshana | 220
Jubilant Pharmova Ltd reported a strong performance for the first quarter of FY26, with its consolidated net profit rising 48% year-on-year to INR 60 crore, up from INR 41 crore in Q1 FY25. Total revenue for the quarter grew 10% to INR 1,650 crore, compared to INR 1,500 crore in the corresponding period last year.
Market | 30/07/2025 | By Darshana | 408
Torrent Pharma Posts INR 3,178 Cr Revenue in Q1 FY26, Net Profit Up 20% on Strong Domestic Growth
Torrent Pharmaceuticals reported a revenue of INR 3,178 crore for the first quarter of FY26, marking a 10% increase compared to the same period last year. The company also posted a 20% year-on-year rise in net profit, which stood at INR 449 crore for the quarter.
Market | 29/07/2025 | By Darshana | 151
India's Pharma Sector Shows Strategic Maturity Amid Global Tariff Shocks: Rubix Report
In this dynamic environment, Rubix Data Sciences, a leading provider of risk management and compliance monitoring solutions, has released a comprehensive industry report that captures how Indian pharmaceutical companies are navigating volatility by focusing on complex generics, regulatory strength, and global expansion.
Market | 24/07/2025 | By Darshana | 245
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy